Lupin Launches Luforbec® 100/6 for Adult Asthma and COPD Treatment in Germany

Hormosan Pharma GmbH (Hormosan), Lupin's wholly-owned subsidiary in Germany, announced the launch of Luforbec® 100/6 (beclometasone 100 µg / formoterol 6 µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.

Luforbec® 100µg/6µg pMDI is indicated for adult asthma and COPD treatment, where the use of an inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) is suitable. With the same active ingredients as Foster® 100/6 pMDI and an extra fine formulation, Luforbec® offers the same licensed indications and similar device characteristics. Luforbec® pMDI provide significant cost savings, priced at - 47% below the fixed reference price on the pharmacy selling price.

With a significant portion of the population (5% of adults and 10% of children) currently undergoing asthma treatment, Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals. This launch reflects Lupin's unwavering commitment to addressing the critical needs of asthma management in Germany.

Anjan Selz, Managing Director, Hormosan Pharma GmbH, added, "The launch of Luforbec® 100/6 pMDI in Germany represents a significant milestone in our goal to establish Hormosan as a key player in the inhalation segment. We are committed to improving healthcare outcomes by ensuring the accessibility and affordability of reliable and comprehensive solutions for patients and healthcare professionals. This launch reinforces our dedication to making asthma and COPD management more accessible for the German population."

Shares of Lupin Limited was last trading in BSE at Rs. 945.75 as compared to the previous close of Rs. 932.40. The total number of shares traded during the day was 25935 in over 1460 trades.

The stock hit an intraday high of Rs. 947.35 and intraday low of 932.40. The net turnover during the day was Rs. 24406789.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 HormosanPharmaGmbH Luforbec Launch pMDI Asthma COPD Treatment Germany